TRACING THE VIRUS

AESKU.GROUP offers now six new quantitative AESKULISA SARS-CoV-2 tests. Fast, reliable and easy to automate.Read more

AESKULISA SARS-CoV-2 IgM

Serves for determination of a first specific reaction of the immune system. Our tests are quantitative immunoassays for the demonstration of human IgM antibodies in serum or plasma.Read more

AESKULISA SARS-CoV-2 IgA

Assists in the detection of acute infections. Our tests are quantitative immunoassays for the demonstration of human IgA antibodies in serum or plasma.Read more

AESKULISA SARS-CoV-2 IgG

Serves for confirmation of pathogen contact and supports in immune status determination. Our tests are quantitative immunoassays for the demonstration of human IgG antibodies in serum or plasma.Read more

MEET US AT

Due to the actual situation, we are currently refraining from participating in trade fairs!Find out more about….

The Innovation Celebration featured next-generation healthcare products to support critical medical needs.

The HELIOS is a new revolutionary platform that employs automated immunofluorescence (IFA) technology to process and analyze patient samples. It is the first clinical diagnostics platform to offer automation of the IFA process to this extent.

The Innovation Celebration took place during Premier’s 2017 Breakthroughs Conference and Exhibition, a week-long event that brings together more than 4,000 representatives from hospitals and health systems, suppliers and other healthcare organizations to share best practices and proven methods to improve quality while safely reducing costs.